Skip to content

US · NBP · BIOTECHNOLOGY

NovaBridge Biosciences (NBP) intrinsic value and stock valuation

$0.83as of 2026-11-21 · Mkt cap 189.04M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

NovaBridge Biosciences DCF and intrinsic value

InvestorsCraft values NBP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NBP’s statements →

NovaBridge Biosciences Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Rockville, MD 20850 novabridge.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-6.61M
20172025
Free cash flow
-$-20.6M
20172025
Total equity
$33M-64.2% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$4.49M-$-10.7M$88M
Operating income-$-13.48M-$-375.36M-$-511.16M-$-366.08M-$-2.07B
Net income-$-6.61M-$-162.26M-$-1.47B-$-967.52M-$-2.33B
EPSd-$-158.74K-$-2M-$-17.61M-$-11.72M-$-30.69M
Operating cash flow-$-20.6M-$-384.42M-$-72.85M-$-1.1B-$-973.09M
Capital expenditure-$-10K-$-350K-$-160K-$-45.83M-$-29.93M
Free cash flow-$-20.6M-$-384.77M-$-73.02M-$-1.15B-$-1B
Total assets$37.2M$1.55B$368.9M$4.07B$878.7M
Total debt$440K$28.3M$3.89M$38.3M$17.6M
Net debt-$-29.67M-$-469.9M-$-287.62M-$-3.18B-$-535.16M
Total equity$33M$1.47B$242.6M$3.01B$715.3M
Cash and short-term investments$30.1M$1.27B$311.7M$3.45B$671M
Income statement
20252024202320222021
Revenue$0.00$0.00$4.49M-$-10.7M$88M
Cost of revenue$0.00$0.00$0.00$0.00$46.4M
Gross profit$0.00$0.00$4.49M-$-10.7M$41.6M
Research and development expenses$8.99M$158.9M$114.4M$155.5M$190.3M
Selling, general and administrative expenses$4.48M$216.5M$63.9M$199.9M$899.9M
Other expenses$0.00$0.00$337.4M-$0.00$1.02B
Operating expenses$13.5M$375.4M$515.7M$355.4M$2.11B
Cost and expenses$13.5M$375.4M$515.7M$355.4M$2.16B
Interest income$1.09M$54.6M$7.3M$4.95M$21.3M
Interest expense$0.00$0.00$100K$0.00$0.00
Depreciation and amortization$120K$1.91M$3.37M$9.7M$13.8M
Ebitda-$-13.35M-$-373.45M-$-344.25M-$-356.38M-$-2.06B
Operating income-$-13.48M-$-375.36M-$-511.16M-$-366.08M-$-2.07B
Total other income/expenses, net$850K$12.6M-$-954.53M-$-607.09M-$-260.73M
Income before tax-$-12.63M-$-362.73M-$-1.47B-$-973.17M-$-2.33B
Income tax expense$0.00$0.00-$-1.26B-$-5.65M-$-490K
Net income-$-6.61M-$-162.26M-$-1.47B-$-967.52M-$-2.33B
Weighted average shares outstanding$41.6M$81.2M$83.2M$82.5M$75.9M
Weighted average diluted shares outstanding$41.6M$81.2M$83.2M$82.5M$76M
Balance sheet
20252024202320222021
Cash and short-term investments$30.1M$1.27B$311.7M$3.45B$671M
Net receivables$260K$0.00$1.83M$4.81M$61M
Inventory$0.00$0.00$0.00-$-80.28M$4.27M
Total current assets$31.1M$1.29B$329.9M$3.63B$750.2M
Property, plant and equipment, net$420K$27.7M$5.55M$124M$24.9M
Goodwill and intangible assets$0.00$0.00$0.00$281.5M$44.3M
Long-term investments$5.32M$225M$0.00$30.9M$55.2M
Total non-current assets$6.15M$262.7M$39M$447.2M$128.6M
Total assets$37.2M$1.55B$368.9M$4.07B$878.7M
Accounts payable$0.00$0.00$0.00$0.00$0.00
Short-term debt$130K$5.96M$630K$6.22M$4.81M
Deferred revenue$0.00$0.00$0.00$2.19M$370K
Total current liabilities$3.84M$61.7M$58.1M$659.7M$97.9M
Long-term debt$310K$22.4M$3.26M$32.1M$12.8M
Deferred revenue, non-current$0.00$0.00$110K$0.00$37.5M
Total non-current liabilities$380K$22.4M$68.2M$405.6M$65.5M
Capital lease obligations$440K$28.3M$3.89M$35.5M$17.6M
Total liabilities$4.23M$84.1M$126.3M$1.07B$163.4M
Common stock$0.00$140K$20K$130K$20K
Retained earnings-$-190.47M-$-9.39B-$-1.26B-$-6.77B-$-683.21M
Accumulated other comprehensive income (loss)$5.94M$243.7M$39.8M$216.7M-$-29.26M
Total equity$33M$1.47B$242.6M$3.01B$715.3M
Total investments$5.35M$992.3M$20.2M$266.3M$173.4M
Total debt$440K$28.3M$3.89M$38.3M$17.6M
Net debt-$-29.67M-$-469.9M-$-287.62M-$-3.18B-$-535.16M
Cash flow statement
20252024202320222021
Net income-$-88.34M-$-362.72M-$-208.18M-$-2.51B-$-2.33B
Depreciation and amortization$860K$7.14M$1.06M$63.8M$34.1M
Stock-based compensation$5.97M-$-14.23M$10.3M$357.2M$608.6M
Change in working capital$17.1M-$-20.52M-$-37.2M$552.1M$394.5M
Accounts receivable$0.00$0.00$0.00$33.1M$97.4M
Inventory$0.00$0.00$0.00$27.2M-$-27.24M
Accounts payable$0.00$0.00$0.00$0.00$107.9M
Net cash provided by operating activities-$-20.6M-$-384.29M-$-72.85M-$-1.1B-$-973.09M
Investments in property, plant and equipment-$-10K-$-350K-$-160K-$-45.83M-$-29.93M
Acquisitions, net$0.00$0.00$0.00$0.00-$-6M
Net cash used for investing activities$105M-$-992.42M-$-107.63M$458.4M-$-727.21M
Common stock issued$61.9M$0.00$0.00$0.00$0.00
Common stock repurchased$0.00-$-2.45M-$-8.66M-$-3.08M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$57.7M-$-2.44M-$-8.25M$42.4M$593.9M
Net change in cash$142.4M-$-1.71B-$-151.58M-$-212.86M-$-1.24B
Cash at end of period$210.6M$498.1M$311.3M$3.31B$3.52B
Operating cash flow-$-20.6M-$-384.42M-$-72.85M-$-1.1B-$-973.09M
Capital expenditure-$-10K-$-350K-$-160K-$-45.83M-$-29.93M
Free cash flow-$-20.6M-$-384.77M-$-73.02M-$-1.15B-$-1B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About NovaBridge Biosciences

        NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.

        CEO
        Srishti Gupta
        Employees
        30
        Beta
        1.45

        Explore

        Frequently asked questions

        What is the intrinsic value of NovaBridge Biosciences (NBP)?

        InvestorsCraft does not currently publish an intrinsic value for NBP. How the IC value is calculated.

        Is NBP undervalued?

        InvestorsCraft does not publish an undervaluation signal for NBP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.